28/11/2014 01:55:42 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
11/25/20141:00PMBWMerck Announces Increased Quarterly Dividend
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has increased the company’s quarterly dividend to $0.45 per outstanding share of the company’s common stock, up $0.01 from $0.44 per outstanding share paid last quarter. Payment will be made on Jan. 8, 2015... More...>>
11/24/20149:57AMDJNBristol-Myers, Five Prime to Collaborate on Immunotherapy
By Tess Stynes Bristol-Myers Squibb Co. (BMY) and Five Prime Therapeutics Inc. (FPRX) agreed to collaborate on potential combinations of their investigational immunotherapies to treat six types of cancers. Five Prime shares rose 14.3% to $18 in recent premarket trading. Immunotherapy drugs work by unleashing the body's... More...>>
11/24/20148:00AMBWMerck Submits New Drug Application to the Japanese Pharmaceuticals & Medical Devices Agency for Omarigliptin, an Investigatio...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the company has submitted a new drug application for omarigliptin, its investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). “Merck is... More...>>
11/24/20147:30AMBWMerck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine
Clinical Development, Manufacturing Expertise, and Scale Critical to Success Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ:NLNK), announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute... More...>>
11/17/201411:45AMBWVYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Present...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN® (ezetimibe/simvastatin) – which combines simvastatin... More...>>
11/17/201411:41AMDJNU.S. Stocks Bounce Back from Early Loses
By Dan Strumpf And Saumya Vaishampayan Stocks bounced back from early losses as investors shrugged off weak economic data from Japan and focused on indications that Europe's central bank could enact additional stimulus measures. The Dow Jones Industrial Average gained three points to 17638 in midmorning trading, rebounding... More...>>
11/17/20148:30AMBWMerck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sess...
Data are Embargoed by American Heart Association until 10:45 AM CT Today Merck (NYSE:MRK), known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed... More...>>
11/17/20145:11AMDJNPfizer, Germany's Merck to Develop Tumor Treatment -- Update
By Natalia Drozdiak and Christopher Alessi FRANKFURT-- Pfizer Inc. and Germany's Merck KGaA are teaming up to develop a new tumor treatment product, in a move that will boost the U.S. company's oncology business but reduce its full-year earnings per share. Merck said Monday it would receive $850 million upfront to jointly... More...>>
11/16/20147:31PMBWMSD annonce une étude positive évaluant l’utilisation de pembrolizumab par rapport à la chimiothérapie chez les patient...
Pembrolizumab a démontré des résultats supérieurs par rapport à la chimiothérapie pour le critère principal de survie sans progression Les conclusions présentées pour la première fois à l’édition 2014 du congrès international de la Society of Melanoma Research (SMR) MSD, plus connu sous l’appellation Merck... More...>>
11/16/20147:30PMBWMSD meldet positive Ergebnisse der Vergleichsstudie für Pembrolizumab und Chemotherapie bei Ipilimumab-therapierefraktären ...
Pembrolizumab zeigt bessere Wirkung als Chemotherapie in Bezug auf den primären Endpunkt des progressionsfreien Überlebens Ergebnisse werden erstmals auf dem Internationalen Kongress der Society of Melanoma Research (SMR) 2014 präsentiert MSD, in den USA und Kanada als Merck firmierend, meldete heute, dass die vorgegebene... More...>>
11/16/20142:12PMBWMSD annuncia risultati positivi per lo studio clinico sull'uso di pembrolizumab rispetto alla chemioterapia nei pazienti con ...
Pembrolizumab ha dimostrato un'efficacia superiore rispetto alla chemioterapia per l'endpoint primario della sopravvivenza libera da progressione I risultati sono stati presentati per la prima volta al congresso internazionale 2014 della Society of Melanoma Research (SMR) MSD, conosciuta negli Stati Uniti e in Canada con... More...>>
11/16/20144:25AMBWMerck Announces Positive Study Investigating the Use of KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in Patients with ...
KEYTRUDA Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that a pre-specified analysis of investigational... More...>>
11/16/20144:25AMBWMSD Announces Positive Study Investigating the Use of Pembrolizumab Compared to Chemotherapy in Patients with Ipilimumab-Refr...
Pembrolizumab Demonstrated Superiority to Chemotherapy for Primary Endpoint of Progression-Free Survival Findings Presented for First Time at Society of Melanoma Research (SMR) 2014 International Congress MSD, known as Merck in the United States and Canada, announced today that a pre-specified analysis of investigational... More...>>
11/11/20148:00AMBWMerck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype ...
Final Results from the C-WORTHy Study (Parts A and B) Presented at The Liver Meeting® and Published in The Lancet First Wave of Phase 3 Development Program for Grazoprevir/Elbasvir is Fully Enrolled; Merck Plans to Submit New Drug Application in 2015 Merck (NYSE:MRK), known as MSD outside the United States and Canada... More...>>
11/09/20146:53PMBWInterim Data from Proof-of-Concept Study of Merck’s Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combinati...
Merck Plans to Initiate Phase 2 C-CREST Program to Evaluate Merck’s Triple Combination of Grazoprevir/Elbasvir with MK-3682 (formerly IDX21437), a Novel Nucleotide Inhibitor, in Q1 2015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT... More...>>
11/07/201411:00AMPRNUSCelebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics Wit...
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal Culinary Expert Visits Los Angeles on November 9 to Help Educate At-Risk Population About Ingredients for Successful Blood Sugar Management PR Newswire... More...>>
11/06/20149:08AMBWNew Studies Investigating the Use of KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Advanced Melanoma Compared t...
By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA® (pembrolizumab) – the company’s anti-PD-1 therapy... More...>>
11/05/20148:30AMBWMerck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
Extensive review and analysis of research data completed Final stage to focus on planned in-field use studies Best Management Practices and Certification Program adopted FDA approval of updates to Zilmax label, including new feed delivery method Merck Animal Health (known outside the United States and Canada as MSD Animal... More...>>
11/03/20145:00AMBWMerck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patie...
Phase 3 Clinical Trial Enrollment Scheduled to Start by the End of 2014 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from a Phase 2b clinical trial evaluating the safety and efficacy of once-daily oral doravirine, an investigational next-generation non-nucleoside... More...>>
10/27/20144:37PMDJNMARKET SNAPSHOT: Energy Stocks Sap S&P 500
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch NEW YORK (MarketWatch) -- The U.S. stock market bounced between gains and losses before wrapping up Monday's relatively benign trading session mostly unchanged. The S&P 500 (SPX) closed 3 points, or 0.2%, lower at 1,961.63, with energy and materials dragging down... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk141128 01:55